Accordingto Bank of America Securities' initial coverage report, AP301's revenue in the Chinese market could reach ...

As per the agreement, CSL will hand over $355m upfront and up to $1.2bn in potential commercial milestone payments to join Alentis in its efforts to develop and commercialise the novel drug across ...

(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

New grant program supporting innovations in early detection and accurate diagnosis of kidney failure to be announced at summit ...

Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in ...

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation are on Capitol Hill with more than 80 advocates who are living with rare kidney diseases to urge elected officials to support ...

Summary:The company released its 2026 interim report, reporting revenue of RMB 1.148 billion for the first half of 2026, up ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...